NCT00037752|CompletedDMC
Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates
SUCCESS
Use of Sibutramine in Smoking Cessation
Loading search results
SUCCESS
Use of Sibutramine in Smoking Cessation
Sponsor study identifier
Secondary identifiers
NIH
interventional
436
1 country
1
Study Start
September 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2008
Actual (reported)Study Completion
August 2008
Actual (reported)The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 20, 2002
Actual (reported)May 21, 2002
Actual (reported)September 2002
Date type not reportedThis date has not been verified as actual or estimated.
August 2008
Actual (reported)August 2008
Actual (reported)Post-cessation weight change
Measured at 1 year follow-up
Smoking cessation
Measured at 1 year follow-up
Sibutramine plus a behavioral smoking cessation program
Placebo sibutramine plus a behavioral smoking cessation program
At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
University of Tennessee Health Science Center
Memphis, Tennessee, 38163, United States
DeBon M, Johnson KC, Bush A, and Klesges RC. (2008, March). The efficacy of sibutramine to prevent or decrease post cessation weight gain in overweight and obese smokers. Paper presented at the 29th annual meeting of the Society of Behavioral Medicine, San Diego, CA. March 2008.
Karen C. Johnson, MD, MPH
University of Tennessee
436 participants (actual enrollment reported by the registry).
First Submitted
May 20, 2002
First Posted
May 21, 2002
Study Start
September 2002
Date type not reportedThis date has not been verified as actual or estimated.
Cafeteria-Based Study of Weight Gain Prevention
Both groups of participants will take part in a behavioral smoking cessation program.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
August 2008
Actual (reported)Study Completion
August 2008
Actual (reported)Last Updated
May 21, 2014
Record last verified: 2014-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: